Table 1.
Comparison of characteristics between CNCP OST patients group and CNCP control group in 2015.
| CNCP OST patients group | CNCP control group | P-value | |
|---|---|---|---|
| N = 8,499 | N = 1,989 | ||
| % (N) | % (N) | ||
| Age (years), mean (±SD) | 42.9 ± 8.6 | 44.9 ± 8.8 | < 0.0001 |
| AGE CLASS | |||
| ≤40 | 37.9 (3,218) | 30.6 (608) | < 0.0001 |
| > 40 | 62.1 (5281) | 69.4 (1381) | |
| Male gender | 71.3 (6,059) | 65.1 (1,295) | < 0.0001 |
| Low-income status | 23.7 (2,017) | 25.7 (511) | 0.07 |
| HIV infection | 2.4 (200) | 1.0 (20) | 0.0002 |
| HCV infection | 7.5 (634) | 0.5 (10) | < 0.0001 |
| HBV infection | 0.3 (22) | 0.4 (8) | 0.28 |
| Alcohol use disorder | 7.9 (670) | 4.0 (79) | < 0.0001 |
| Mental health disorder | 80.7 (6,857) | 57.5 (1,143) | < 0.0001 |
| Number of different OST prescribers, median [IQR]a | 2 [1-2] | – | – |
| Buprenorphine | 68.9 (5,857) | – | – |
| Buprenorphine ± naloxone | 4.1 (346) | – | – |
| Methadone | 30.9 (2,617) | – | – |
| Capsule | 66.5 (1,510) | – | – |
| Syrup | 33.5 (761) | – | – |
| Switch buprenorphine/methadone | 0.2 (25) | – | – |
CNCP, chronic non-cancer pain; OST, opioid substitution treatment; HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; IQR, interquartile range (25th and 75th percentiles).
a
Total number of different OST prescribers used by opioid-maintained patients during 2015.